Active Substance: irbesartan / hydrochlorothiazide
Common Name: irbesartan / hydrochlorothiazide
ATC Code: C09DA04
Marketing Authorisation Holder: Sanofi Clir SNC
Active Substance: irbesartan / hydrochlorothiazide
Authorisation Date: 1998-10-15
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Agents acting on the renin-angiotensin system
Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.
What is CoAprovel?
CoAprovel is a medicine that contains two active substances, irbesartan and hydrochlorothiazide. It is available as tablets (150Â mg or 300Â mg irbesartan and 12.5Â mg hydrochlorothiazide; 300Â mg irbesartan and 25Â mg hydrochlorothiazide).
What is CoAprovel used for?
CoAprovel is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by irbesartan or hydrochlorothiazide alone. â€˜Essentialâ€™ means that the hypertension has no obvious cause.
The medicine can only be obtained with a prescription.
How is CoAprovel used?
The dose of CoAprovel to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before. Doses higher than 300Â mg irbesartan and 25Â mg hydrochlorothiazide once a day are not recommended. CoAprovel may be added to some other treatments for hypertension.
How does CoAprovel work?
CoAprovel contains two active substances, irbesartan and hydrochlorothiazide.
Irbesartan is an â€˜angiotensin-II-receptor antagonistâ€™, which means that it blocks the action of a hormone in the body called angiotensinÂ II. AngiotensinÂ II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensinÂ II normally attaches, irbesartan stops the hormone having an effect, allowing the blood vessels to widen.
Hydrochlorothiazide is a diuretic, which is another type of treatment for hypertension. It works by increasing urine output, reducing the amount of fluid in the blood and lowering the blood pressure.
The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.
How has CoAprovel been studied?
Irbesartan on its own has been approved in the European Union (EU) since 1997 under the names Karvea and Aprovel. It can be used with hydrochlorothiazide to treat hypertension. The studies of Karvea / Aprovel used with hydrochlorothiazide as separate tablets were used to support the use of CoAprovel. Further studies were also carried out with doses of 300Â mg irbesartan in combination with 25Â mg hydrochlorothiazide. The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).
What benefit has CoAprovel shown during the studies?
CoAprovel was more effective than placebo (a dummy treatment) and than hydrochlorothiazide alone in reducing diastolic blood pressure. Increasing the dose to 300Â mg irbesartan and 25Â mg hydrochlorothiazide may give a further decrease in blood pressure.
What is the risk associated with CoAprovel?
The most common side effects with CoAprovel (seen in between 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, abnormal urination, fatigue (tiredness), and increases in blood urea nitrogen (BUN, a breakdown product of protein), creatinine (a breakdown product of muscle) and creatine kinase (an enzyme found in muscle). For the full list of all side effects reported with CoAprovel, see the package leaflet.
CoAprovel must not be used in people who are hypersensitive (allergic) to irbesartan, hydrochlorothiazide, sulfonamides, or any of the other ingredients. It must not be used in women who are more than three months pregnant. Its use during the first three months of pregnancy is not recommended. CoAprovel must also not be used in patients who have severe liver, kidney or bile problems, blood potassium levels that are too low or blood calcium levels that are too high.
CoAprovel in combination with aliskiren-containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment. Care must be taken when using CoAprovel with other medicines that have an effect on blood potassium levels. The full list of these medicines is given in the package leaflet.
Why has CoAprovel been approved?
The CHMP decided that CoAprovelâ€™s benefits are greater than its risks and recommended that it be given marketing authorisation.
Other information about CoAprovel
The European Commission granted a marketing authorisation valid throughout the EU for CoAprovel on 15 October 1998.
For more information about treatment with CoAprovel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.